Zantrene – Race Oncology

Pitt Street Research Initiates Coverage of Race Oncology

Daniel Tillett Featured, Media Release, OPINION EDITORIAL approval, Biotech, cancer, drug, Race Oncology, Zantrene

Race Oncology Limited (ASX:RAC) is an Australian pharmaceutical company focused on the development of its key drug, Zantrene, which is currently being studied for pre-clinical and clinical efficacy in several cancer indications. Zantrene is a highly targeted precision oncology agent…

30 Jun

Zantrene Protects Mouse Hearts from Chemotherapy Damage

Daniel Tillett ASX Release, Featured, Media Release cardioprotection, Race Oncology, Zantrene

30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021). This program aimed at exploring the…

Tag: Zantrene

Race Submits Human Ethics Application to Commence Cardioprotection Breast Cancer Trial

Race Oncology 2022 AGM Presentation

Race Receives Positive Guidance on Zantrene via Pre-IND Meeting with US FDA

Race Oncology EMD AML Trial Featured on NBN News

Race Oncology Investor Briefing – Melbourne 20th Oct 2022

Pitt St Research interview with Race Oncology’s CEO Phil Lynch & CSO Dr Daniel Tillett

Pitt Street Research Initiates Coverage of Race Oncology

Race Develops Improved IV Formulation of Zantrene

Race Initiates FTO & ALKBH5 Drug Discovery Program

Zantrene Protects Mouse Hearts from Chemotherapy Damage

Race Oncology

Newsletter

Get the latest News and Updates